We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current PNEXF market cap is 2.19T. The company's latest EPS is EUR -314.3902 and P/E is -79519.02.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 255k | 21k | 4.39M | 7.43M | 174k |
| Operating Income | -23.58M | -20.76M | -25.77M | -27.52M | -23.86M |
| Net Income | -22.75M | -21.02M | -25.18M | -28.44M | -27.52M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 22.84M | 21.55M | 16.2M | 6.59M | 4.17M |
| Total Liabilities | 31.21M | 34.74M | 35.67M | 40.98M | 38.12M |
| Total Equity | -8.36M | -13.19M | -19.47M | -34.38M | -33.95M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -21.57M | -16.15M | -23.56M | -25.54M | N/A |
| Investing | 175k | -177k | -58k | 434k | N/A |
| Financing | 15.08M | 11.15M | 20.51M | 17.53M | N/A |
| Market Cap | 2.19T |
| Price to Earnings Ratio | -79519.02 |
| Price to Sales Ratio | 12.58M |
| Price to Cash Ratio | 168.35M |
| Price to Book Ratio | -64.45k |
| Dividend Yield | - |
| Shares Outstanding | 87.53k |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Pharnext (CE) |
| Address |
14 rue de la republique suresnes, hauts-de-seine 92150 |
| Website | https://pharnext.com/ |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
